<DOC>
	<DOCNO>NCT00489476</DOCNO>
	<brief_summary>The objective trial ass efficacy safety Staccato Loxapine patient migraine headache without aura clinical setting .</brief_summary>
	<brief_title>Staccato® Loxapine Inhalation Patients With Migraine Headache</brief_title>
	<detailed_description>This study enroll male female patient migraine headache without aura . The study randomize ~160 patient , 1:1:1:1 receive one follow treatment : 1.25 mg Staccato Loxapine ; 2.5 mg Staccato Loxapine ; 5 mg Staccato Loxapine ; Staccato Placebo .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<criteria>1 . Male female patient age 18 65 year , inclusive . 2 . Patients migraine headache without aura ( diagnosis accord International Headache Society guideline ) least 6 month . 3 . Patients history migraine least 3 migraine attack last 3 month period ( 8 migraine attack last month ) . 4 . Patients pain free least 48 hour since end last migraine attack . 5 . Patients take acute migraine pain medication within 48 hour prior dose ( include OTC product ) . 6 . Patients pain rating Moderate Severe ( NoneMild ModerateSevere Scale ) prior dose . 7 . Patients speak , read , understand English willing able provide write informed consent IRB approve form prior initiation study procedure . 8 . Patients willing able comply study schedule requirement , willing able travel Clinical Research Unit ( CRU ) treatment stay CRU approximately 46 hour period , agree return clinic within 5 work day use investigational treatment . 9 . Patients good general health prior study participation determine detailed medical history , physical examination , 12lead ECG , blood chemistry profile , hematology , urinalysis , opinion Principal Investigator . 10 . Female participant ( childbearing potential sexually active ) male participant ( sexually active partner childbearing potential ) agree use medically acceptable effective birth control method throughout study one week follow end study . Medically acceptable method contraception may use participant and/or his/her partner include abstinence , birth control pills patch , diaphragm spermicide , intrauterine device ( IUD ) , condom foam spermicide , vaginal spermicidal suppository , surgical sterilization , progestin implant injection . Prohibited method include : rhythm method , withdrawal , condoms alone , diaphragm alone . 1 . Patients currently take antipsychotic , tricyclic antidepressant , valproate , barbiturate , benzodiazepine , lithium must exclude . 2 . Patients history contraindication anticholinergic ( bowel obstruction , urinary retention , acute glaucoma ) must exclude . 3 . Patients history allergy intolerance dibenzoxazepines ( loxapine amoxapine ) must exclude . 4 . Patients history extrapyramidal disorder , movement disorder include Parkinson 's disease , patient history neuroleptic malignant syndrome must exclude . 5 . Female patient positive pregnancy test screen randomization visit , breastfeed must exclude . 6 . Patients history within past year drug alcohol dependence abuse define DSM4 must exclude . 7 . Patients history syncope , unstable angina , myocardial infarction ( within 6 month ) , congestive heart failure , transient ischemic attack , pheochromocytoma must exclude . 8 . Patients history major neurological disorder migraine ( seizure disorder , subarachnoid bleeding , stroke , brain tumor ) must exclude . 9 . Patients disease ( ) , history , physical examination , laboratory abnormality ( ALT AST &gt; 2fold upper limit normal , Bilirubin &gt; 1.5 mg/dL , creatinine &gt; 1.8 mg/dL ) investigator 's opinion , would present undue risk patient may confound interpretation study result must exclude . 10 . Patients history asthma chronic obstructive lung disease exclude . 11 . Patients receive investigational drug within 30 day prior Screening Visit must exclude . 12 . Patients consider investigator , reason , unsuitable candidate receiving loxapine , unable use inhalation device , must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Staccato® Loxapine , Migraine</keyword>
</DOC>